Icosapent ethyl for reduction in cardiovascular disease risk in adults with hypertriglyceridaemia

伊索拉贝特用于高甘油三酯血症成年人降低心血管疾病风险的效果评估

Australian prescriber. 2024 Dec;47(6):197-198.

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap

ethyl在高甘油三酯血症中的疗效和安全性：回顾

Klaus G Parhofer

European heart journal supplements : journal of the European Society of Cardiology. 2020 Oct 6;22(Suppl J):J21-J33.

Hypertriglyceridaemia - REDUCE-IT with icosapent ethyl

高甘油三酯血症的药物治疗：依洛尤单抗（伊索莫司乙酯）REDUCE-LIT研究

Gregory B Lim

Nature reviews. Cardiology. 2019 Jan;16(1):1.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies

依帕立塑乙酯（二十碳五烯酸乙酯）对残余样颗粒胆固醇的影响：MARINE研究和ANCHOR研究结果

Christie M Ballantyne et al.

Atherosclerosis. 2016 Oct:253:81-87.

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial

乙酯二十碳五烯酸对他汀类药物治疗且甘油三酯水平升高患者冠状动脉粥样硬化进展的影响：EVAPORATE试验的最终结果

Matthew J Budoff et al.

European heart journal. 2020 Oct 21;41(40):3925-3932.

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

伊索替康乙酯减少血运重建的机制：REDUCE-IT 血管成形术分析结果给我们的启示

Benjamin E Peterson et al.

Circulation. 2021 Jan 5;143(1):33-44.

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study

依折麦布对他汀治疗患者血脂升高的冠状动脉粥样硬化进展的影响：EVAPORATE研究的目的和设计(甘油三酯水平为200-499 mg/dL)

Matthew Budoff et al.

Clinical cardiology. 2018 Jan;41(1):13-19.

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

乙酯二十碳五烯酸可降低既往有冠状动脉旁路移植术史患者的缺血事件：REDUCE-IT CABG研究

Subodh Verma et al.

Circulation. 2021 Dec 7;144(23):1845-1855.